|
|
|
7 May, 2010
New packaging line FDA-certified
BASEL, SWITZERLAND - Legacy Pharmaceuticals Switzerland is now ready for the US market. A new packaging area has been successfully approved by the American Food and Drug Administration (FDA). Customer orders will be manufactured from June onwards.
7 October, 2009
Production waste powers district heating
BASEL, SWITZERLAND - Taking care of the environment is a high priority for Legacy Pharmaceuticals. This is why, since the end of October 2008, liquid organic waste from this drug manufacturer has been used to produce biogas.
17 September, 2009
New packaging line for the US market
BASEL, SWITZERLAND - Thanks to the participation of a client, Legacy Pharmaceuticals Switzerland is in a position to invest in the construction of a new packaging line. This is to be inspected by the United States Food and Drug Administration (FDA), opening the door to the largest single market in the world.
|
|
23 July, 2009
Legacy at the company running event in Basel
BASEL, SWITZERLAND - The fourth edition of the Swiss companies running event is already history. All employees of Legacy Pharmaceuticals reached the finishing line.
25 June, 2009
Legacy participates at the Swiss companies running event (Schweizer Firmenlauf) in Basel
BASEL, SWITZERLAND - After the first participation at the running event last summer, the employees of Legacy Pharmaceuticals will be part of the “Schweizer Firmenlauf” this year again.
26 May, 2008
Solco Healthcare US is formed and Management Team named
BASEL, SWITZERLAND - Legacy Pharmaceuticals International GmbH announced today that Jeff Cole and Shafi Rahman have joined the management team. Jeff and Shafi will lead Solco Healthcare US, which is a new Legacy business unit formed to conduct our generic pharmaceuticals business in the United States market.
22 April, 2008
Legacy Puerto Rico Celebrates Earth Day
HUMACAO, PUERTO RICO - Zaida Berrios, Site Manager, and team observe Earth Day in Humacao, Puerto Rico.
Click on images for a larger view.
|
12 January, 2008
M&A Advisor Honors Legacy Pharmaceuticals International
NEW YORK, NY - M&A Advisor Honors Legacy Pharmaceuticals International pharmaceutical plant acquisitions with "Life Sciences Deal of the Year" Award.
5 June, 2007
Legacy Pharmaceuticals International to purchase two Valeant Sites
ALISO VIEJO, CA - Legacy Pharmaceuticals International has agreed to purchase pharmaceutical manufacturing sites at Humacao, Puerto Rico and Basel, Switzerland from Valeant Pharmaceuticals International. Selected Valeant brands will also be sold to Legacy and the deal is expected to close within the next few weeks. Legacy is a contract manufacturing and specialty pharmaceutical company formed by former managers of the facilities.
read more...
continued:
|
Mike Danzi, Legacy Chairman and CEO said, The creation of Legacy marks a step change in direction for the Humacao and Basel sites, enabling each of these sites to capitalize on its competitive advantages. Our core competencies support our mission of customer-focused contract manufacturing of large and small volume products. Legacy is also seeking to expand its ownership and licensing of difficult to produce niche drugs.
Humacao specializes in high volume contract manufacturing and packaging of over-the-counter and prescription drugs, oral solids (capsules and tablets), semi-solids (i.e. topical creams) and liquids (i.e. oral syrups).
The Basel facility specializes in sterile parenterals, as well as semi-solids. Products include sterile injectibles, creams and ointments.
Danzi added, At Humacao, our goal is to increase capacity utilization by winning manufacturing and packaging contracts from large pharmaceutical companies, who are increasingly outsourcing production. In addition, we expect to take advantage of the continued growth of generic drugs. Our mission is to provide customer focused FDA and Swiss Medic approved contract manufacturing to reduce our customers cost of goods sold.
While Legacy is a new company, all Legacy employees and managers have worked together at the previous owner. This team has worked together in the buyout process and in setting this new strategic direction for the sites and brands. It is an exciting time for our industry and for everyone involved in Legacy," Danzi concluded.
-end-
For further information, in the first instance please contact: Tim Kaye, PR+International Communications + 44 208 392 3926 or at tck@prplus.demon.co.uk | |
|
|
|
